Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
News and updates on AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) focus on its role as a therapeutic acute wound care company centered on the RECELL System and related wound care technologies. Company news frequently highlights developments in thermal burn and trauma treatment, clinical evidence for its products, and regulatory milestones in key markets.
Investors following RCEL news can expect coverage of financial results, revenue updates, and capital structure actions such as credit agreements and equity placements, as disclosed in Form 8-K filings and press releases. AVITA Medical regularly reports quarterly and annual financial performance, adjustments to revenue outlook, and steps taken to align operating expenses with its growth priorities.
News flow also includes clinical and scientific updates. AVITA Medical has reported data presentations at medical conferences, including systematic reviews of peer-reviewed literature and real-world registry analyses supporting the RECELL System in acute wound treatment. These items describe outcomes such as reduced donor site burden, faster healing, shorter hospital stays, and favorable economic impact in burn care.
Regulatory and market access developments are another recurring theme. The company has announced CE Mark approval for RECELL GO under the EU Medical Device Regulation, regulatory clearances for RECELL in Europe, Australia, and Japan, and support from Australia’s Medical Services Advisory Committee for the use of autologous skin cell suspension prepared with RECELL in severe burns. Corporate governance updates, such as board appointments and executive transitions, are also disclosed through AVITA Medical’s news releases.
For readers tracking RCEL, this news stream provides insight into the company’s clinical progress, regulatory status, financial performance, and leadership changes, all of which shape its position in the acute wound care and medical device landscape.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company specializing in wound care management and skin restoration devices, has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets close. The company will host a conference call and webcast at 1:30 p.m. Pacific Time on the same day (8:30 a.m. AEDT on November 8, 2024) to discuss the results and recent business highlights.
Investors can access the live webcast through the Events & Presentations section of AVITA Medical's website. For telephone participation, pre-registration is required. A replay of the webcast will be available on the Investor Relations website shortly after the event.
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leader in regenerative medicine and wound care management, has announced its participation in the 2024 Cantor Global Healthcare Conference. David O'Toole, the company's Chief Financial Officer, will present on Wednesday, September 18, 2024, at 9:10 a.m. Eastern Time.
Investors and interested parties can access a live webcast of the presentation through the Events & Presentations section of AVITA Medical's website at https://ir.avitamedical.com. For those unable to attend the live event, a replay of the webcast will be made available following the conclusion of the conference.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a leader in regenerative medicine and wound care management, has announced its participation in the 8th Annual Best Ideas Growth (BIG8) Conference organized by Lake Street Capital Markets. The event is scheduled for September 12, 2024, in New York.
CEO Jim Corbett will be present to conduct one-on-one meetings with institutional investors throughout the day. This conference provides AVITA Medical with an opportunity to showcase its first-in-class devices for wound care and skin restoration to potential investors.
Interested parties are encouraged to contact their Lake Street representative for more information or to schedule a meeting with AVITA Medical's management team.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a leader in regenerative medicine for wound care and skin restoration, has announced an upcoming investor webinar briefing on August 13, 2024, at 4:00 p.m. PDT (August 14, 2024, at 9:00 a.m. AEST). The presentation will be led by CEO Jim Corbett and CFO David O'Toole, covering financial and business results from the company's recent second-quarter 2024 earnings.
Shareholders and potential investors are invited to attend the webinar, which will include a Q&A session. Participants can submit questions through the registration page. The event will be hosted via Zoom, with a replay available on the AVITA Medical website following the presentation.
AVITA Medical (NASDAQ: RCEL) reported strong Q2 2024 financial results, with commercial revenue reaching $15.1 million, a 29% increase year-over-year. The company achieved a gross profit margin of 86.2%. Key highlights include FDA approval of RECELL GO™ and submission of a PMA supplement for RECELL GO mini™. AVITA entered an exclusive agreement with Regenity Biosciences for a collagen-based dermal matrix.
The company expects Q3 2024 commercial revenue between $19.0-$20.0 million and full-year 2024 revenue of $68.0-$70.0 million. AVITA anticipates achieving cashflow break-even and GAAP profitability by Q3 2025. Despite strong growth, the company reported a net loss of $15.4 million for Q2 2024, compared to $10.4 million in Q2 2023. As of June 30, 2024, AVITA had $54.1 million in cash and equivalents.
AVITA Medical (NASDAQ: RCEL, ASX: AVH) has appointed Robin VanDenburgh as Senior Vice President of U.S. Commercial Sales, effective August 6, 2024. VanDenburgh, previously Vice President of Key Accounts at Smith & Nephew, brings over 25 years of experience in healthcare sales leadership. CEO Jim Corbett expressed confidence in VanDenburgh's ability to expand market presence and drive sales growth for AVITA's wound care solutions, particularly the RECELL GO product.
VanDenburgh's extensive background includes 12 years at Smith & Nephew in senior sales management roles within their advanced wound division. She has also held key positions at Aureon Biosciences, St. Jude Medical, and Ethicon Endo-Surgery. Her expertise in building high-performing sales teams and driving new product adoption is expected to accelerate AVITA Medical's commercial success in the U.S. market.
AVITA Medical (NASDAQ: RCEL, ASX: AVH) has entered an exclusive multi-year development and distribution agreement with Regenity Biosciences for a unique collagen-based dermal matrix. Following FDA 510(k) clearance, expected in Q4 2024, AVITA will have exclusive rights to market, sell, and distribute the product in the U.S. and potentially in EU countries, Australia, and Japan.
The collaboration aims to enhance AVITA's wound care portfolio by integrating Regenity's bioresorbable materials with AVITA's RECELL technology. AVITA plans to initiate clinical studies in 2025 to demonstrate improved outcomes and establish a new standard of care for full-thickness wounds.
The agreement includes a $2 million payment upon 510(k) clearance and up to $3 million by January 2026 for manufacturing support. Revenue sharing starts at 50% for the first two years, increasing to 60% thereafter.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company, announced it will report its Q2 2024 financial results on August 8, 2024, after U.S. market close. The company will host a conference call and webcast to discuss the results and recent business highlights at 1:30 p.m. PT (August 9, 2024, at 6:30 a.m. AEST). The live webcast can be accessed via AVITA Medical's Investor Relations website, where a replay will also be available. To join the call by telephone, prior registration is required to receive dial-in details and a personal PIN.
AVITA Medical (NASDAQ: RCEL), a leader in regenerative medicine devices for wound care and skin restoration, announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer and Corporate Secretary, effective July 1, 2024. Kelsey, with over 20 years of executive legal experience in M&A, securities, and governance, previously held senior roles at Amyris, Criteo, and Medtronic. Her international expertise is expected to bolster AVITA's legal and compliance strategies, aiding its commercial growth.
Donna Shiroma, the outgoing General Counsel, retires after six years of distinguished service. AVITA's CEO, Jim Corbett, praised Shiroma's contributions and leadership, which have significantly impacted the company's growth.
AVITA Medical has achieved a significant milestone with the first use of its FDA-approved RECELL GO System at the Joseph M. Still Burn Center. The RECELL GO System is an advanced cell harvesting device designed to treat thermal burn wounds and full-thickness skin defects using a patient's own skin cells. This next-generation device enhances healing, reduces pain, and minimizes the need for donor skin. AVITA plans to roll out RECELL GO to top U.S. burn centers in June, with a full deployment throughout the year. The device promises to streamline medical procedures and improve patient outcomes.
FAQ
What is the current stock price of Avita Medical (RCEL)?
What is the market cap of Avita Medical (RCEL)?
